Bridges Investment Management Inc. Has $9.02 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Bridges Investment Management Inc. decreased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 4.7% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 10,924 shares of the company's stock after selling 540 shares during the quarter. Bridges Investment Management Inc.'s holdings in Eli Lilly and Company were worth $9,022,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Alpha Financial Partners LLC grew its stake in Eli Lilly and Company by 8.1% during the 1st quarter. Alpha Financial Partners LLC now owns 493 shares of the company's stock valued at $407,000 after acquiring an additional 37 shares in the last quarter. Topsail Wealth Management LLC grew its position in Eli Lilly and Company by 6.2% during the first quarter. Topsail Wealth Management LLC now owns 776 shares of the company's stock valued at $641,000 after purchasing an additional 45 shares in the last quarter. Moloney Securities Asset Management LLC increased its stake in Eli Lilly and Company by 6.0% in the 1st quarter. Moloney Securities Asset Management LLC now owns 6,877 shares of the company's stock valued at $5,679,000 after buying an additional 388 shares during the period. Banque Pictet & Cie SA lifted its position in Eli Lilly and Company by 8.0% in the 1st quarter. Banque Pictet & Cie SA now owns 88,282 shares of the company's stock worth $72,913,000 after buying an additional 6,505 shares in the last quarter. Finally, Wealth Advisory Solutions LLC boosted its stake in shares of Eli Lilly and Company by 18.0% during the 1st quarter. Wealth Advisory Solutions LLC now owns 19,171 shares of the company's stock valued at $15,834,000 after buying an additional 2,924 shares during the period. Institutional investors own 82.53% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on LLY shares. Cantor Fitzgerald started coverage on Eli Lilly and Company in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price target for the company. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and decreased their target price for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Erste Group Bank downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their price objective for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. Finally, Wall Street Zen cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Saturday, June 28th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $1,012.56.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded up $2.69 during trading hours on Friday, hitting $793.34. The stock had a trading volume of 2,851,585 shares, compared to its average volume of 3,675,715. The company has a 50-day moving average of $766.39 and a two-hundred day moving average of $800.06. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53. The company has a market cap of $751.88 billion, a PE ratio of 64.55, a price-to-earnings-growth ratio of 1.16 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. During the same quarter in the previous year, the company posted $2.58 earnings per share. The business's revenue for the quarter was up 45.2% compared to the same quarter last year. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.76%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.